Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

5(71.4%)

N/A

1(14.3%)

Phase 2

1(14.3%)

7Total

Phase 1(5)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04903080Phase 1Active Not Recruiting

HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma

Role: collaborator

NCT05010564Phase 1Recruiting

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

Role: collaborator

NCT04525014Phase 1Terminated

RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

Role: collaborator

NCT02076997Not ApplicableCompleted

Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate

Role: collaborator

NCT02794207Completed

Home or Away From Home - Descriptive Interviews (Aim 2)

Role: collaborator

NCT00016861Phase 1Completed

Irinotecan in Treating Children With Refractory or Progressive Solid Tumors

Role: lead

NCT00003241Phase 2Completed

Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors

Role: lead

NCT00186862Phase 1Completed

Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma

Role: collaborator

All 8 trials loaded